Is NEUROCRINE BIOSCIENCES INC (NBIX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.2% / 30% | 11.5% / 30% | 5.3% / 30% | 3.16% / 5% | ✓ HALAL |
| DJIM | 3.2% / 33% | 11.5% / 33% | 5.3% / 33% | 3.16% / 5% | ✓ HALAL |
| MSCI | 9.0% / 33% | 32.0% / 33% | 14.8% / 33% | 3.16% / 5% | ✓ HALAL |
| S&P | 3.2% / 33% | 11.5% / 33% | 5.3% / 33% | 3.16% / 5% | ✓ HALAL |
| FTSE | 9.0% / 33% | 32.0% / 33% | 14.8% / 50% | 3.16% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 62.7% | |
| Operating Margin | 28.2% | |
| Net Margin | 16.7% | |
| Return on Equity (ROE) | 16.4% | |
| Return on Assets (ROA) | 9.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $783M |
| Free Cash Flow | $749M |
| Total Debt | $415M |
| Debt-to-Equity | 14.5 |
| Current Ratio | 3.4 |
| Total Assets | $4.6B |
Price & Trading
| Last Close | $132.42 |
| 50-Day MA | $132.14 |
| 200-Day MA | $137.07 |
| Avg Volume | 1.1M |
| Beta | 0.4 |
|
52-Week Range
$84.23
| |
About NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Purification Calculator
As a halal stock with 3.16% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NEUROCRINE BIOSCIENCES INC (NBIX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NEUROCRINE BIOSCIENCES INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NEUROCRINE BIOSCIENCES INC's debt ratio?
NEUROCRINE BIOSCIENCES INC's debt ratio is 3.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.0%.
Does NEUROCRINE BIOSCIENCES INC require dividend purification?
Yes, NEUROCRINE BIOSCIENCES INC has an impermissible income ratio of 3.16%, which means 3.16% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are NEUROCRINE BIOSCIENCES INC's key financial metrics?
NEUROCRINE BIOSCIENCES INC has a market capitalization of $12.9B, trailing P/E ratio of 27.5, and revenue of $2.9B. The company maintains a gross margin of 62.7% and a net margin of 16.7%. Return on equity stands at 16.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.